Home Cart Sign in  
Chemical Structure| 104632-26-0 Chemical Structure| 104632-26-0
Chemical Structure| 104632-26-0

*Storage: Keep in dark place,Inert atmosphere,2-8°C.

Pramipexole

CAS No.: 104632-26-0

,99%

Pramipexole is an agonist of dopamine receptors D2, D3, and D4 (Ki = 3.9, 2.2, 0.5, and 5.1 nM respectively) and it is indicated for treating Parkinson's disease (PD) and restless legs syndrome (RLS).

4.5 *For Research Use Only !

99%98%
Cat. No.: A2667518 Purity: 99%

Change View

Size Price

USA Stock *0-1 Day

Global Stock *5-7 Days

In Stock

Please Login or Create an Account to: See VIP prices and availability

    In Stock

    - +

    Please Login or Create an Account to: See VIP prices and availability

    • 1-2 Day Shipping
    • High Quality
    • Technical Support Online Technical Q&A
    Product Citations

    Product Details of [ 104632-26-0 ]

    CAS No. :104632-26-0
    Formula : C10H17N3S
    M.W : 211.33
    SMILES Code : CCCN[C@H]1CCC2=C(C1)SC(N)=N2
    MDL No. :MFCD00869076
    InChI Key :FASDKYOPVNHBLU-ZETCQYMHSA-N
    Pubchem ID :119570

    Safety of [ 104632-26-0 ]

    GHS Pictogram:
    Signal Word:Warning
    Hazard Statements:H302
    Precautionary Statements:P280-P305+P351+P338

    Calculated chemistry of [ 104632-26-0 ] Show Less

    Physicochemical Properties

    Num. heavy atoms 14
    Num. arom. heavy atoms 5
    Fraction Csp3 0.7
    Num. rotatable bonds 3
    Num. H-bond acceptors 2.0
    Num. H-bond donors 2.0
    Molar Refractivity 61.17
    TPSA ?

    Topological Polar Surface Area: Calculated from
    Ertl P. et al. 2000 J. Med. Chem.

    79.18 Ų

    Lipophilicity

    Log Po/w (iLOGP)?

    iLOGP: in-house physics-based method implemented from
    Daina A et al. 2014 J. Chem. Inf. Model.

    2.28
    Log Po/w (XLOGP3)?

    XLOGP3: Atomistic and knowledge-based method calculated by
    XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

    1.86
    Log Po/w (WLOGP)?

    WLOGP: Atomistic method implemented from
    Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

    1.59
    Log Po/w (MLOGP)?

    MLOGP: Topological method implemented from
    Moriguchi I. et al. 1992 Chem. Pharm. Bull.
    Moriguchi I. et al. 1994 Chem. Pharm. Bull.
    Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

    1.01
    Log Po/w (SILICOS-IT)?

    SILICOS-IT: Hybrid fragmental/topological method calculated by
    FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

    2.64
    Consensus Log Po/w?

    Consensus Log Po/w: Average of all five predictions

    1.88

    Water Solubility

    Log S (ESOL):?

    ESOL: Topological method implemented from
    Delaney JS. 2004 J. Chem. Inf. Model.

    -2.39
    Solubility 0.864 mg/ml ; 0.00409 mol/l
    Class?

    Solubility class: Log S scale
    Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

    Soluble
    Log S (Ali)?

    Ali: Topological method implemented from
    Ali J. et al. 2012 J. Chem. Inf. Model.

    -3.14
    Solubility 0.152 mg/ml ; 0.000718 mol/l
    Class?

    Solubility class: Log S scale
    Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

    Soluble
    Log S (SILICOS-IT)?

    SILICOS-IT: Fragmental method calculated by
    FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

    -3.07
    Solubility 0.18 mg/ml ; 0.000853 mol/l
    Class?

    Solubility class: Log S scale
    Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

    Soluble

    Pharmacokinetics

    GI absorption?

    Gatrointestinal absorption: according to the white of the BOILED-Egg

    High
    BBB permeant?

    BBB permeation: according to the yolk of the BOILED-Egg

    No
    P-gp substrate?

    P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
    and tested on 415 molecules (test set)
    10-fold CV: ACC=0.72 / AUC=0.77
    External: ACC=0.88 / AUC=0.94

    No
    CYP1A2 inhibitor?

    Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
    and tested on 3000 molecules (test set)
    10-fold CV: ACC=0.83 / AUC=0.90
    External: ACC=0.84 / AUC=0.91

    Yes
    CYP2C19 inhibitor?

    Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
    and tested on 3000 molecules (test set)
    10-fold CV: ACC=0.80 / AUC=0.86
    External: ACC=0.80 / AUC=0.87

    No
    CYP2C9 inhibitor?

    Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
    and tested on 2075 molecules (test set)
    10-fold CV: ACC=0.78 / AUC=0.85
    External: ACC=0.71 / AUC=0.81

    No
    CYP2D6 inhibitor?

    Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
    and tested on 1068 molecules (test set)
    10-fold CV: ACC=0.79 / AUC=0.85
    External: ACC=0.81 / AUC=0.87

    No
    CYP3A4 inhibitor?

    Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
    and tested on 2579 molecules (test set)
    10-fold CV: ACC=0.77 / AUC=0.85
    External: ACC=0.78 / AUC=0.86

    No
    Log Kp (skin permeation)?

    Skin permeation: QSPR model implemented from
    Potts RO and Guy RH. 1992 Pharm. Res.

    -6.27 cm/s

    Druglikeness

    Lipinski?

    Lipinski (Pfizer) filter: implemented from
    Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
    MW ≤ 500
    MLOGP ≤ 4.15
    N or O ≤ 10
    NH or OH ≤ 5

    0.0
    Ghose?

    Ghose filter: implemented from
    Ghose AK. et al. 1999 J. Comb. Chem.
    160 ≤ MW ≤ 480
    -0.4 ≤ WLOGP ≤ 5.6
    40 ≤ MR ≤ 130
    20 ≤ atoms ≤ 70

    None
    Veber?

    Veber (GSK) filter: implemented from
    Veber DF. et al. 2002 J. Med. Chem.
    Rotatable bonds ≤ 10
    TPSA ≤ 140

    0.0
    Egan?

    Egan (Pharmacia) filter: implemented from
    Egan WJ. et al. 2000 J. Med. Chem.
    WLOGP ≤ 5.88
    TPSA ≤ 131.6

    0.0
    Muegge?

    Muegge (Bayer) filter: implemented from
    Muegge I. et al. 2001 J. Med. Chem.
    200 ≤ MW ≤ 600
    -2 ≤ XLOGP ≤ 5
    TPSA ≤ 150
    Num. rings ≤ 7
    Num. carbon > 4
    Num. heteroatoms > 1
    Num. rotatable bonds ≤ 15
    H-bond acc. ≤ 10
    H-bond don. ≤ 5

    0.0
    Bioavailability Score?

    Abbott Bioavailability Score: Probability of F > 10% in rat
    implemented from
    Martin YC. 2005 J. Med. Chem.

    0.55

    Medicinal Chemistry

    PAINS?

    Pan Assay Interference Structures: implemented from
    Baell JB. & Holloway GA. 2010 J. Med. Chem.

    0.0 alert
    Brenk?

    Structural Alert: implemented from
    Brenk R. et al. 2008 ChemMedChem

    0.0 alert: heavy_metal
    Leadlikeness?

    Leadlikeness: implemented from
    Teague SJ. 1999 Angew. Chem. Int. Ed.
    250 ≤ MW ≤ 350
    XLOGP ≤ 3.5
    Num. rotatable bonds ≤ 7

    No; 1 violation:MW<1.0
    Synthetic accessibility?

    Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
    based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
    trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

    3.37

    Application In Synthesis [ 104632-26-0 ]

    * All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

    • Downstream synthetic route of [ 104632-26-0 ]

    [ 104632-26-0 ] Synthesis Path-Downstream   1~2

    • 1
    • [ 1046124-81-5 ]
    • [ 68-11-1 ]
    • [ 6375-65-1 ]
    • [ 104632-26-0 ]
    • 2
    • [ 104632-26-0 ]
    • [ 130-85-8 ]
    • pramipexole pamoate [ No CAS ]
    YieldReaction ConditionsOperation in experiment
    99% In dimethyl sulfoxide; ethyl acetate; at 20℃; Pramipexole (5.0 g, 23.44 mmol) and <strong>[130-85-8]Pamoic acid</strong> (9.08 g, 23.44 mmol) was dissolved by stirring at room temperature in DMSO (50 mL). The solution was then slowly added to ethyl acetate (2L) at room temperature to generate a white solid. The solid was collected on a filter and dried in vacuum at 45 °C to give pramipexole pamoate at a 1: 1 Molar ratio of Pramipexole to <strong>[130-85-8]Pamoic acid</strong> (14.0g, 99.0percent).
     

    Related Products

    Historical Records

    Technical Information

    Categories